|
WO2021003194A1
|
|
Eif4e inhibitors for use as immune checkpoint modulators and related methods
|
|
WO2021003192A1
|
|
Methods of treating braf-mutated cancer cells
|
|
WO2021003157A1
|
|
Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds
|
|
WO2021001743A1
|
|
Translation inhibitors and uses thereof
|
|
WO2021001739A1
|
|
Translational enhancers and related methods
|
|
WO2020086713A1
|
|
Crystalline forms of mnk inhibitors
|
|
WO2019079369A1
|
|
Benzimidazole-indole inhibitors of mnk1 and mnk2
|
|
WO2018218038A1
|
|
Methods and compositions for cellular immunotherapy
|
|
CN110891567A
|
|
Compositions and methods for improved anti-tumor immune response
|
|
BR112019016707A2
|
|
mnk inhibitors replaced by piperidine and methods related to them
|
|
WO2017117052A1
|
|
Mnk biomarkers and uses thereof
|
|
AU2016359617A1
|
|
eIF4-A-inhibiting compounds and methods related thereto
|
|
WO2017087808A1
|
|
Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
|
|
US2017121339A1
|
|
Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2
|
|
EP3368530A1
|
|
Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2
|
|
US2016303124A1
|
|
Inhibitors of immune checkpoint modulators and related methods
|
|
TW201613918A
|
|
Mnk inhibitors and methods related thereto
|
|
AU2015213721A1
|
|
Methods for treating fibrotic disease
|
|
WO2015120334A2
|
|
Compositions and methods for treating neurological disorders
|
